Search clinical trials for: Programmed death-ligand 1 (PD-L1)

Total 50343 results

Merck Sharp & Dohme LLC

Completed

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms

United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Singapore, Taiwan
National Cancer Institute (NCI)

Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Cervical Cancer | Vulvar Cancer | Colon Cancer | Anal Cancer | Vaginal Cancer | Oropharyngeal Cancer | Penile Cancer | HPV | Human Papillomavirus | Neck Cancer

United States
Eli Lilly and Company

Completed

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Solid Tumor

United States, Korea, Republic of, Japan, Spain
Addario Lung Cancer Medical Institute
Biodesix, Inc.

Terminated

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-LUNG)

NSCLC Stage IV | NSCLC, Stage IIIC

United States
University Medical Center Groningen

Not yet recruiting

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy (PREDICT)

Locally Advanced Rectal Carcinoma

Netherlands
Cancer Institute and Hospital, Chinese Academy...

Recruiting

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Advanced Lung Carcinoma

China
Pfizer

Terminated

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Melanoma | Soft Tissue Sarcoma | Mycosis Fungoides | Breast Carcinoma | Solid Tumors | Squamous Cell Carcinoma | Human Papillomavirus-Related Malignant Neoplasm | Merkel-cell Carcinoma

United States
OncoC4, Inc.
BioNTech SE

Recruiting

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Non Small Cell Lung Cancer

United States, Belgium, Canada, France, Germany, Italy, Spain, China, Korea, Republic of, Netherlands, Turkey, United Kingdom, Australia
Zhongda Hospital

Recruiting

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (CHANCE2202)

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC

Lung Cancer | Immunotherapy
Jun Zhang, MD, PhD

Recruiting

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

NSCLC Stage IV | NSCLC, Recurrent

United States
Bristol-Myers Squibb

Withdrawn

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin's Lymphoma | Chronic Myelogenous Leukemia
Attikon Hospital

Unknown

Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

DNA Damage | HNSCC | DNA Double Strand Break

Greece
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

Melanoma | Lung Cancer | PD-L1 | PET/CT

China
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Johannes Laengle, MD, PhD
Christian Doppler Laboratory Applied Metabolomics

Recruiting

PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer (PETNEC)

Oesophageal Cancer | Rectal Cancer Stage

Austria
Phanes Therapeutics

Recruiting

Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)

Non Small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Zhongda Hospital

Recruiting

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (CHANCE2201)

Hepatocellular Carcinoma

China
Buzzard Pharmaceuticals
Baylor Research Institute

Recruiting

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Solid Tumor, Adult

United States
Poitiers University Hospital

Active, not recruiting

Radiomics for prEdiction of lunG cAncer biologY

Non Small Cell Lung Cancer | Gene Mutation-Related Cancer | PD-L1 | PET/CT

France
Shanghai General Hospital, Shanghai Jiao Tong University...
NanoMab Technology (UK) Limited

Completed

99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC

Non-Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Recruiting

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Small Cell Lung Cancer | Lung Cancer | Carcinoma, Small Cell

United States
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients (CINSBDRILCP)

Lung Cancer

China
MultiVir, Inc.

Unknown

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Lymphoma | Solid Tumor

United States
Seagen Inc.

Terminated

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Carcinoma, Squamous Cell of Head and Neck | Urinary Bladder Neoplasm

United States
Jounce Therapeutics, Inc.

Terminated

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Cancer

United States
Radboud University Medical Center
AstraZeneca

Completed

PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC (PINCH)

Head and Neck Cancer

Netherlands
Shanghai Chest Hospital

Recruiting

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Lars Møller Pedersen
IO Biotech

Completed

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Chronic Lymphocytic Leukemia

Denmark
Merck Sharp & Dohme LLC

Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Austria, Brazil, France, Israel, Korea, Republic of, Norway, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
RenJi Hospital

Not yet recruiting

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (sPLENTY-pc)

Pediatric Cancer | Liver Cancer | Hepatoblastoma | Pediatric Solid Tumor | Transitional Cell Tumor

China
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Colorectal Neoplasms

United States, Canada
Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
Laekna Limited

Recruiting

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Cervical Cancer | Esophageal Cancer | NSCLC | Solid Tumor | Endometrial Cancer | Gastric and Gastroesophageal Junction Adenocarcinoma

China
Beijing Friendship Hospital

Completed

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Advanced Solid Tumor

China
Maastricht Radiation Oncology
Maastricht University Medical Center; Zuyderland Medical Centre

Completed

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Stage IV Non-small Cell Lung Cancer

Netherlands
Merck Sharp & Dohme LLC

Completed

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Neoplasms | Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Ovarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Colorectal Cancer Microsatellite Stable (MSS)

Canada, Australia, Singapore, United States, Japan, Spain, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Carcinoma, Renal Cell

Poland, Australia, Japan, United States, Korea, Republic of, Taiwan, China, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Romani... and more
Elpiscience Biopharma, Ltd.

Withdrawn

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

Small Cell Lung Cancer | Non-small Cell Lung Cancer | Thoracic Tumors
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Gastric Adenocarcinoma
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
Agenus Inc.

Suspended

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Advanced Melanoma

United States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
Targovax Oy
Agenus Inc.

Withdrawn

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Melanoma
Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction (CHIMeRA)

Autoimmune Diseases | Endocrine System Diseases | Cancer | Arthritis | Myositis | Neuropathy | Cardiac Disease | Ophthalmopathy

France

Search clinical trials for: Programmed death-ligand 1 (PD-L1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations